Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.50 |
| ▸ | NPC1 | O15118 | 12/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.50 |
| ▸ | AR | P10275 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008269 | 0.77 | MAPT (0.50) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31143361 | 0.77 | MAPT (0.50) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7914859 | 0.77 | NPC1 (0.58) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30938000 | 0.77 | NPC1 (0.58) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15190605 | 0.77 | ALDH1A1 (0.39) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2457365 | 0.76 | QPCT (0.50) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL484215 | 0.76 | NPC1 (0.57) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL240431 | 0.76 | NPC1 (0.63) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL34467584 | 0.76 | NPC1 (0.63) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9562898 | 0.76 | NPC1 (0.45) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-8491869-B2 | Imaging agents for detecting neurological disorders | ELI LILLY AND COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010111303-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | RAB9A 1055/4885NPC1 68/4885KDM4E 4835/4885 |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | RAB9A 1434/4885NPC1 143/4885KDM4E 4835/4885 |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | MAPT, APP, PSEN1 | RAB9A 1055/4885NPC1 68/4885KDM4E 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.